Molecular Oncology Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, San Sebastián, 20014, Spain.
Multiple Sclerosis Group, Biodonostia Research Institute, Paseo Doctor Begiristain, s/n, San Sebastián, 20014, Spain.
Semin Cancer Biol. 2019 Oct;58:100-108. doi: 10.1016/j.semcancer.2019.01.003. Epub 2019 Jan 23.
Non-invasive biomarkers or liquid biopsies have the potential to revolutionise cancer patient management as repeated sampling allows real-time monitoring of disease progression and response to treatment. This allows for earlier intervention and dynamic treatment management; both cornerstones of personalised medicine. The circulating transcriptome represents a rich source of potential cancer biomarkers that includes many classes of RNA, both coding and non-coding, that are only now beginning to be explored. In particular the increasing power and availability of RNAseq techniques have pushed studies beyond circulating miRNAs, to other classes of RNA including mRNA, snRNA, snoRNA, piRNA, YRNA, lncRNA and circRNA. In this review we focus on the emerging potential for these different classes of RNA as cancer biomarkers, and in particular the barriers and limitations that remain to be overcome if these molecules are to become part of routine clinical practice.
非侵入性生物标志物或液体活检有可能彻底改变癌症患者的管理方式，因为重复采样可以实时监测疾病进展和对治疗的反应。这可以实现更早的干预和动态治疗管理；这两者都是个性化医疗的基石。循环转录组是潜在癌症生物标志物的丰富来源，其中包括许多种类的 RNA，包括编码和非编码 RNA，目前才刚刚开始探索。特别是 RNAseq 技术的日益强大和可用性，促使研究超越了循环 miRNA，扩展到其他 RNA 类别，包括 mRNA、snRNA、snoRNA、piRNA、YRNA、lncRNA 和 circRNA。在这篇综述中，我们重点介绍了这些不同种类的 RNA 作为癌症生物标志物的新兴潜力，特别是如果这些分子要成为常规临床实践的一部分，仍然存在需要克服的障碍和限制。
